The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Novo Nordisk AS's quick ratio for the quarter that ended in Dec. 2024 was 0.55.
Novo Nordisk AS has a quick ratio of 0.55. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Novo Nordisk AS's Quick Ratio or its related term are showing as below:
LTS:0TDD'
s Quick Ratio Range Over the Past 10 Years
Min: 0.55 Med: 0.73 Max: 1.04
Current: 0.55
During the past 13 years, Novo Nordisk AS's highest Quick Ratio was 1.04. The lowest was 0.55. And the median was 0.73.
LTS:0TDD's Quick Ratio is ranked worse than 85.81% of 1029
companies
in the Drug Manufacturers industry
Industry Median: 1.39
vs LTS:0TDD: 0.55
Novo Nordisk AS Quick Ratio Historical Data
The historical data trend for Novo Nordisk AS's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novo Nordisk AS's Quick Ratio
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS's Quick Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Quick Ratio falls into.
Novo Nordisk AS Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Novo Nordisk AS's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (LTS:0TDD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Novo Nordisk AS Quick Ratio Related Terms
Thank you for viewing the detailed overview of Novo Nordisk AS's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0TDD has been successfully added to your 